Bicycle Therapeutics plc (BCYC)
Develops experimental drugs designed like bicycles to target hard-to-treat cancers and neurological diseases.
The outlook
Bicycle Therapeutics trades near its 52-week low at $3.94, well below its 50- and 200-day averages, though analysts lean bullish with an average target roughly 244% above the current price. The stock's neutral overall score reflects tension between weak recent price momentum and strong analyst conviction, with coverage spread across seven analysts. Current data shows the stock deeply depressed in its range, leaving a significant gap between market price and consensus targets.
What’s behind the score
Analyst price target
~12-month · 7 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.